Abstract:Objective To compare the efficacy and safety of insulin glulisine and insulin lispro combined with insulin glargine in patients with diabetes mellitus. Methods This was a multi-centre randomly controlled study.Thirty four patients with type 1 and 450 patients with type 2 diabetes mellitus with a HbAlc level of 6.5％ to 11.0％ and more than 3 months of continuous insulin treatment immediately prior to study entry were enrolled from February 2007 to June 2008.After 4-week run-in period with insulin lispro (three times a day,0-15 min before the meals) combined with insulin glargine treatment (once daily before breakfast),all the subjects were randomized (3:1 ) to receive a 12-week treatment with insulin glulisine or insulin lispro in combination with insulin glargine.The data collected at the visit after the 4-weeks run-in period was defined as the baseline data.The change in HbAlc,blood glucose,treatment satisfaction and incidence of hypoglycemia after the treatment was recorded and compared.The data of the two groups were compared by using an ANOVA model.Results After 12-week of treatment,HbA1 c reduced from 8.7％ ±1.2％ to7.9％ ±1.0％ in insulin glulisine group,and from 8.8％ ±1.2％ to 7.9％ ±1.0％ in insulin lispro group (compared with baseline,t =- 12.55 and - 8.88,both P ＜0.05).Fasting plasma glucose (FPG) decreased significantly compared with baseline in both groups: for insulin glulisine group,from (8.6 ±2.8) mmoL/L to (7.7 ±2.5) mmoL/L,and for insulin lispro group,from (8.6 ±2.5) mmol/L to (7.8 ± 2.2) mmol/L ( compared with baseline,t =- 6.55 and - 2.98,both P ＜ 0.05 ).The 2 h postprandial glucose (2 h PPG) decreased significantly in insulin glulisine group (from ( 10.6 ± 3.8)mmol/L to ( 10.2 ±3.7) mmol/L,t =- 2.07,P =0.04),but it was no difference in insulin lispro group ( from ( 10.9 ± 4.0) mmol/L to ( 10.4 ± 3.5 ) mmol/L,t =- 1.37,P ＞ 0.05 ).The incidence of all categories of symptomatic hypoglycemia was comparable between the two groups (33.9％ vs 34.7％ ) during treatment period.An increase of satisfaction scores after treatment was found both in the insulin glulisine group (from 29 ±5 to 31 ±5,t =6.81 P ＜0.05) and insulin lispro group (from 29 ±5 to 31 ±4,t =4.21,P ＜0.05).Conclusions It showed that when used in combination with insulin glargine,insulin glulisine is clinical equivalent to insulin lispro in decreasing HbA1c and plasma glucose in Chinese patients with diabetes mellitus.Both regimens are well tolerated and safe.

Effect of Combined Treatment of Glimepiride and Glargine for Type 2 Diabetes Mellitus

Efficacy and Safety of Additional Basal Insulin or Oral Antidiabetic Drug in Type 2 Diabetes Poorly Controlled with One Oral Antidiabetic Drug

Efficacy and Safety of Insulin Glargine Combined with Glimepiride in Type 2 Diabetic Patients with Poor Glycemic Control

Clinical efficacy of glimepiride combined with pioglitazone on glycemic control in type 2 diabetes patients

Comparison on Efficacy and Safety of Two Regimens for Treatment of Type 2 Diabetes Mellitus: Glargine Plus Metformin Versus Neutral Protamine Hagedorn Plus Metformin

Clinical effect of insulin glargine added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes

Comparison of Efficacy and Safety of Liraglutide and Glimepiride in Combination with Metformin in Type 2 Diabetes

The Efficacy and Safety of the Combination Therapy With GLP-1 Receptor Agonists and SGLT-2 Inhibitors in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis

Comparison of the effect of different short-term intensive anti-diabetic therapies on newly diagnosed type 2 diabetic patients.

Meta-analysis of Glargine Combined with Glipizide Extended - Release Tablets in the Treatment of Type Ⅱ Diabetes Patients

Glargine insulin/gliclazide MR combination therapy is more effective than premixed insulin monotherapy in Chinese patients with type 2 diabetes inadequately controlled on oral antidiabetic drugs.

Comparision of glimepiride and glibenclamide on cardiovascular risk factors in patients with newly diagnosed type 2 diabetes mellitus

The Efficacy and Safety of Glimepiride in Treatment of Type 2 Diabetes

Efficacy and Safety of Premixed Human Insulin Combined with Sulfonylureas in Type 2 Diabetic Patients Previously Poorly Controlled with Insulin.

The Effect of Therapy with Glargine on Glucolipid Metabolism and Insulin Detection in Newly Diagnosed Type 2 Diabetic Patients

Effects of Glimepiride on Metabolic Parameters and Cardiovascular Risk Factors in Patients with Newly Diagnosed Type 2 Diabetes Mellitus

Glargine Insulin Plus Repaglinide in the Treatment of Type 2 Diabetes Meta Analysis

The effectiveness and safety of saxagliptin combined with insulin glargine in the treatment of gerontal patients with type 2 diabetes mellitus

Comparison of the Efficacy and Safety of Insulin Glulisine and Insulin Lispro Combined with Insulin Glargine in Patients with Diabetes

Influence of glimepiride plus sitagliptin on treatment outcome, blood glucose, and oxidative stress in diabetic patients

Effectiveness and Safety of Metformin, Teneligliptin, and Glimepiride Combination Therapy in Type 2 Diabetes: A Quasi Experimental Clinical Trial